CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.9% – Should You Sell?

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares were down 0.9% on Friday . The company traded as low as $1.0102 and last traded at $1.06. Approximately 4,295 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 25,638 shares. The stock had previously closed at $1.07.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of CytoMed Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, CytoMed Therapeutics has an average rating of “Sell”.

CytoMed Therapeutics Stock Down 0.9%

The stock has a 50 day simple moving average of $1.05 and a two-hundred day simple moving average of $1.63.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.